ATM

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 27, 2024
CDK4, ESPP, Research, BCL6, Sale, Exercise, LRRK2, ARVN, CDK7, ATM, HER2, Genentech, European Medicines Agency, Congress, Development, Breast cancer, Pfizer, CBR, ESMO, Everolimus, Greyhawk, ESR1, Oncology, Enrollment, Investment, Insurance, Prostate cancer, PFS, Food, Ribociclib, Bayer, Administration, Patient, Neutropenia, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Median PFS of 11.1 and 11.0 months in patients with ESR1 wild-type and ESR1 mutant tumors, respectively.
  • Announced the appointment of Randy Teel, Ph.D., Arvinas’ current senior vice president of corporate and business development, to the role of interim chief financial officer and treasurer.
  • The Arvinas Board of Directors has launched a formal search process to identify Mr. Cassidy’s permanent replacement.
  • Revenues: Revenue was $78.5 million and $(43.1) million for the year and quarter ended December 31, 2023 as compared with $131.4 million and $38.0 million for the year and quarter ended December 31, 2022.

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

Retrieved on: 
Thursday, February 22, 2024
Ulcerative colitis, BID, Research, Biotechnology, Friends, ATM, Cardiac output, AbbVie, Conditional sentence, DDW, Inflammatory bowel disease, Patient, TL1A, Clinical trial, Janssen, IBD, PIPE, Insurance, Pharmaceutical industry

WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2023.

Key Points: 
  • -Ended 2023 with $704.3 million in cash and equivalents; cash runway into second half of 2027-
    WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2023.
  • “Today, our conviction in MORF-057 as a potential oral, well tolerated, and efficacious treatment for inflammatory bowel disease (IBD) is stronger than ever, based on the clear success of the EMERALD-1 trial in UC.
  • Looking forward in 2024, we will work to translate this momentum into further progress with the GARNET phase 2 study in patients with moderately to severely active Crohn’s disease running in parallel with the EMERALD-2 phase 2b study in UC,” commented Praveen Tipirneni, Chief Executive Officer of Morphic.
  • We believe that our cash, cash equivalents and marketable securities of $704.3 million as of December 31, 2023, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2027

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, February 22, 2024
Research, Intellia Therapeutics, Regeneron Pharmaceuticals, Fatigue, Haemophilia, NK, CTA, Liver, Cystic fibrosis, ATM, A1AT, Amyloidosis, HAE, Therapy, European Medicines Agency, ATTR, Haemophilia B, DNA, European Commission, Hereditary angioedema, Recode, Conference, Cardiomyopathy, AATD, Civil service commission, Clinical trial, Facial muscles, CRISPR, Gene editing, Food, NTLA, KLKB1, Lung, NEJM, TTR, Patient, Medicine, Disease, Tissue, Pharmaceutical industry

Collaboration Revenue: Collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022.

Key Points: 
  • Collaboration Revenue: Collaboration revenue decreased by $15.5 million to negative $1.9 million during the fourth quarter of 2023, compared to $13.6 million during the fourth quarter of 2022.
  • R&D Expenses: Research and development expenses increased by $9.0 million to $109.0 million during the fourth quarter of 2023, compared to $100.0 million during the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses increased by $5.4 million to $29.0 million during the fourth quarter of 2023, compared to $23.6 million during the fourth quarter of 2022.
  • Net Loss: The Company’s net loss was $132.2 million for the fourth quarter of 2023, compared to $113.4 million during the fourth quarter of 2022.

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 22, 2024
BRAF, PD, Research, International Myeloma Foundation, Sale, Lung cancer, Workforce, Poster, Melanoma, P-value, Clinical trial, ATM, BCMA, Therapy, CCCC, Roche, Completeness, CRC, AACR, Conference, Colorectal cancer, Merck, NHL, Research and development, Cancer, Dexamethasone, Administration, Patient, Finance, Biogen, Pharmaceutical industry

WATERTOWN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the year ended December 31, 2023, as well as recent business updates.

Key Points: 
  • As of February 2024, three escalation cohorts are complete and dose escalation continues with a fourth dose level currently enrolling.
  • In December 2023, C4T and Merck entered into a license and research collaboration to discover and develop degrader antibody conjugates.
  • Net loss per share for the year ended December 31, 2023 was $2.67, compared to $2.62 for the year ended December 31, 2022.
  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of December 31, 2023 were $281.7 million, compared to $337.1 million as of December 31, 2022.

Operational Security Solutions (OSS) Releases 2023 Highlights and Expansion Roadmap for 2024

Retrieved on: 
Wednesday, February 21, 2024
Bitcoin, ATM, B2C, Software architecture, American City Business Journals, Financial institution, Research, Pressure, Risk management, OSS, Growth, Federal Reserve, Sport, Documentation, Operational definition, FIS, Specialization, Organic, Organization, Tax, Fintech, CIT, Bitcoin ATM, Bank

FRESNO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Operational Security Solutions (“OSS”), the premier provider of full-spectrum risk management services with specialization in secure cash management and logistics, compliance services, security consulting, and facility hardening, today released highlights from 2023 operations and its expansion roadmap for 2024 as the company eyes further market saturation on the East Coast and new sector offerings.

Key Points: 
  • FRESNO, CA, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Operational Security Solutions (“OSS”), the premier provider of full-spectrum risk management services with specialization in secure cash management and logistics, compliance services, security consulting, and facility hardening, today released highlights from 2023 operations and its expansion roadmap for 2024 as the company eyes further market saturation on the East Coast and new sector offerings.
  • Last year, OSS made significant strides in further establishing its presence as a predominant player on the East Coast .
  • This geographic service expansion paired with the several new service offerings launched by the Company, aided in sustaining revenue throughout 2023.
  • Accordingly, the OSS Security Consulting division experienced heavy demand for assistance at the beginning of 2023 that gradually tapered off by the end of the year.

VEON Launches Geolocation Gateway, Enabling Proximity-Based Digital Services

Retrieved on: 
Wednesday, February 21, 2024
Infobip, Nokia, Flood, ATM, GSMA, Growth, Communication, API, Earthquake, Application, Euronext Amsterdam, Geopositioning, VEON, Partnership, Internet service provider

Initiative builds on GSMA Open Gateway framework, ensuring international interoperability

Key Points: 
  • Initiative builds on GSMA Open Gateway framework, ensuring international interoperability
    Amsterdam and Tashkent, 21 February 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, today announced the launch of the Geolocation Gateway with the first implementation already in place in Uzbekistan.
  • The Geolocation Gateway, developed by VEON in partnership with Nokia and Infobip, allows applications to determine the location of devices.
  • "Mobile operators are at the forefront when it comes to enabling economic growth through digitalization, especially in the emerging economies where VEON operates.
  • The solution will be scaled to other digital operators of the VEON Group and is also available for licensing by other mobile operators.

Group Financial Results as of December 31st 2023 Approved, Strong Margin Expansion and Excess Cash Generation at € 601 Million, € 500 Million Share Buy-Back Program

Retrieved on: 
Thursday, March 7, 2024
Finance, Banking, Professional Services, Other Professional Services, Insurance, Acquisition, International, Y/Y, EV, Total, Shareholder, POS, SIA, Investment, Record, DACH, Partnership, ATM, Culture, Growth, WooCommerce, Overalls, ESG, NetZero, Human, Volume, PwC, ISP, Tax, EPS, Omnichannel, E-commerce, Book, Partner, FX, Cardboard

"In 2023, we have continued our growth journey across all geographies, we have further increased our margins, and significantly accelerated cash generation.

Key Points: 
  • "In 2023, we have continued our growth journey across all geographies, we have further increased our margins, and significantly accelerated cash generation.
  • In FY23 the Group delivered revenues at € 3,361.7 million, +7.0% versus FY22, and EBITDA at € 1,751.8 million, +10.0% versus FY22.
  • 4Q23 EBITDA was at € 484.1 million, +9.7% versus 4Q22, with EBITDA margin at 53%, up by 139 basis points compared to 4Q22.
  • In FY23, 18,524 million transactions were processed, +12.6% Y/Y, with value of processed transactions at € 825.3 billion, +7.6% Y/Y.

Soluna Inks Agreement with Noteholders to Bolster Balance Sheet Ahead of Halving

Retrieved on: 
Friday, March 1, 2024
Data Management, Technology, Professional Services, Blockchain, Web3, Software, Cryptocurrency, Alternative Energy, Fintech, Energy, Finance, Bitcoin, ATM, Growth, Floor, Annual report, Security (finance)

John Belizaire, CEO of Soluna Holdings, commented, “We are progressively tuning our capital formation approach to take advantage of the growth opportunities on the horizon for the company.

Key Points: 
  • John Belizaire, CEO of Soluna Holdings, commented, “We are progressively tuning our capital formation approach to take advantage of the growth opportunities on the horizon for the company.
  • The ATM Floor is eliminated once the aggregate principal balance of the notes is less than $1.5 million.
  • Pursuant to additional agreements with holders of another 46,618 outstanding warrants the resulting total of Repriced Warrants is 530,569.
  • Statements that are not historical facts, including but not limited to statements about Soluna’s beliefs and expectations, are forward-looking statements.

MFA Financial, Inc. Announces New Stock Repurchase and ATM Programs

Retrieved on: 
Thursday, February 29, 2024
Professional Services, Other Professional Services, Other Construction & Property, Finance, Construction & Property, REIT, ATM, Sale, MFA

MFA Financial, Inc. (NYSE: MFA) (the “Company”) announced today that its Board of Directors has authorized a new $200 million stock repurchase program with respect to the Company’s common stock, which will be in effect through the end of 2025.

Key Points: 
  • MFA Financial, Inc. (NYSE: MFA) (the “Company”) announced today that its Board of Directors has authorized a new $200 million stock repurchase program with respect to the Company’s common stock, which will be in effect through the end of 2025.
  • The Company's prior stock repurchase program, which was adopted in March 2022, had authorized the repurchase of up to $250 million of common stock and expired on December 31, 2023, with approximately $202.5 million remaining available at the date of expiration.
  • The new stock repurchase program supersedes the prior stock repurchase program in its entirety.
  • The new stock repurchase program does not require the purchase of any minimum number of shares.

WestPark Capital Announces Closing of $10.8 Million Public Offering of Common Stock for Wetouch Technology Inc (Nasdaq: WETH )

Retrieved on: 
Wednesday, February 28, 2024
Professional Services, Technology, Audio, Video, Finance, Banking, Hardware, WETH, Prospectus, Biotechnology, Suite, Health, ATM, Sale, Form, RDS, TEL, Form S-1, Offering, Research, Software

WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the closing of a $10.8 Million public offering for Wetouch Technology Inc. (Nasdaq: WETH ).

Key Points: 
  • WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the closing of a $10.8 Million public offering for Wetouch Technology Inc. (Nasdaq: WETH ).
  • The offering consisted of 2,160,000 shares of common stock at a price to the public of $5.00 per share (the “Offering”).
  • WestPark Capital, Inc. served as lead book running manager for the Offering.
  • The shares of common stock described above were offered by the Company pursuant to a registration statement on Form S-1 (File No.